
Novo Nordisk raises 2026 cash flow forecast, eyes cautious growth amid patent risks and competition
Novo Nordisk updated its 2026 free cash flow guidance to 60–70 billion DKK, supported by lower capital expenditure and a diversified product pipeline including the Wegovy pill. The company expects adjusted sales and operating profit to grow modestly ...




